Sequana Medical NV Overview
Sequana Medical was a Ghent-headquartered, Zurich-manufacturing medical technology company that pioneered device- and drug-based treatments for diuretic-resistant fluid overload. Its flagship, the alfapump®, is a fully implanted, wirelessly charged pump that moves ascitic fluid from the abdomen to the bladder for natural voiding, and in December 2024 became the first active implantable device approved by the US FDA (PMA P230044) for recurrent or refractory ascites due to liver cirrhosis. A second platform, DSR® (Direct Sodium Removal), a sodium-free peritoneal infusate for cardiorenal syndrome in heart failure, reached Phase 1/2a. Despite regulatory success, CE-mark history since 2011, more than 1,000 implants and a US commercial launch in Q4 2025, the company never generated meaningful revenue, accumulated losses approaching EUR 270m, carried negative equity from 2021 onward and relied on serial dilutive financings. It filed for bankruptcy in June 2026; its value now resides in IP, regulatory dossiers, inventory and know-how being marketed by court-appointed trustees.
Company's own description (FY2024 results release / H1 2025 report, paraphrased). Sequana Medical described itself as a pioneer in treating fluid overload — a serious and frequent complication in liver disease, heart failure and cancer that drives mortality, repeat hospitalisation, pain, breathlessness and restricted mobility. Because diuretics become ineffective, intolerable or counter-productive in many patients, the company positioned its two proprietary platforms, alfapump® and DSR®, as working "with the body" to treat this diuretic-resistant population while reducing healthcare costs. In its final business descriptions (late 2025 to April 2026) the company emphasised US commercialisation of the alfapump through a specialty team targeting the ~90 US liver transplant centres that perform more than 90% of US liver transplants, CMS approval of a New Technology Add-on Payment (NTAP) from 1 October 2025, and a DSR randomised cohort that was approved by its DSMB but dependent on financing.
Independent characterisation. Functionally, Sequana was a pre-revenue, single-asset implantable-device company with an attached early-stage drug programme. Its economic engine was capital markets access rather than sales: across FY2021–FY2024 it generated EUR 2.1m of cumulative revenue against EUR 131.6m of cumulative net losses. The company's value chain position was that of an integrated OEM: it designed, assembled (Zurich), obtained regulatory approval for and (in the US) directly sold a Class III active implantable device, while DSR was being developed as a proprietary pharmaceutical-type infusate (DSR 2.0, a sodium-free dextrose/icodextrin solution) administered via peritoneal catheter. The strategic arc was: (1) build a European clinical and commercial base (2012–2023); (2) exit European sales in Q1 2024 to conserve cash; (3) pivot entirely to the US with PMA approval (Dec 2024) and a Q4 2025 launch; (4) attempt to finance DSR separately. The model failed on the time-to-revenue versus cash-runway equation rather than on regulatory or clinical evidence.
Business and revenue model.
Strategy
Stated strategy themes (latest disclosures, paraphrased). (1) Commercialise the alfapump in the US through a small specialty salesforce focused on ~90 liver transplant centres; (2) secure and leverage US reimbursement (CPT III, ICD-10, NTAP); (3) a two-phase US rollout — "Soft Launch" (≥70 implants at up to eight centres through end-Q1 2026) followed by "Full Launch" from Q2 2026 adding about five centres per quarter; (4) finance DSR separately, either within the company or as a standalone entity, to broaden the investor universe; (5) reduce cash burn and convert debt into equity.
Strategic initiatives register (last 24 months)
ESG/sustainability commitments: none publicly disclosed. Medium-term financial targets: none beyond implant and centre-opening targets.
Products & Services
alfapump® System (liver / oncology programme)
| Attribute | Detail |
|---|---|
| Description | Fully implanted, programmable, wirelessly charged, battery-powered subcutaneous pump that automatically and continuously moves ascites from the peritoneal cavity to the bladder for elimination by urination |
| Regulatory — US | FDA Breakthrough Device designation (2019); PMA approval 20 Dec 2024 (P230044) for adult patients with recurrent or refractory ascites due to liver cirrhosis; first US-approved active implantable device (Class III) for this indication |
| Regulatory — EU | CE mark 2011 (refractory ascites due to cirrhosis); CE-marked also for malignant ascites; MDR certification by BSI, Feb 2022 |
| Regulatory — Canada | Not approved |
| Key evidence | POSEIDON (18 centres US/Canada; pivotal cohort 40 patients): 100% median per-patient reduction in therapeutic paracentesis at 6 months; 77% with ≥50% reduction; virtual elimination of paracentesis sustained to 24 months; QoL improvement (SF-36 PCS, Ascites Q); ~10 additional good-health days per month; 24-month overall survival 62% in pivotal cohort (AASLD Nov 2024); published American Journal of Gastroenterology Jan 2025. Post-hoc EASL 2026: 10 of 48 patients with functioning pump at 6 months achieved recompensation (median 519 days). European PMSR published Liver International (2022) |
| Safety profile | Six primary safety events in pivotal cohort (three explants for wound/skin erosion, three for patient-reported discomfort); MRI unsafe; risks include infection, peritonitis, pump migration, catheter complications, renal function decline, hepatic encephalopathy |
| Installed base | >1,000 implants worldwide (company, 2025) |
| Target customer | US liver transplant centres (90 centres performing >90% of transplants); hepatologists and interventional radiologists |
| Launch / latest version | EU launch 2012; US commercial launch Q4 2025 (first implant 24 Nov 2025) |
| Pricing model | Capital-free per-unit sale; anticipated US ASP ~USD 30,000; NTAP top-up up to USD 21,450 |
| Named commercial sites (US) | Mount Sinai Hospital (NY), University of Pennsylvania, an unnamed "leading US liver transplant centre", Dartmouth Hitchcock Medical Center, University Medical Center of Southern Nevada |
DSR® (Direct Sodium Removal) — heart failure programme
| Attribute | DSR 1.0 | DSR 2.0 |
|---|---|---|
| Description | First-generation sodium-free infusate (used with alfapump-based delivery originally, then catheter) | Proprietary sodium-free dextrose/icodextrin solution administered via peritoneal catheter; short-term intensive therapy (3–4 weeks) aimed at ≥12 months of benefit |
| Mechanism | Diffusion of sodium into sodium-free peritoneal infusate, removed with fluid; positioned as breaking the cardiorenal vicious cycle and restoring diuretic response | Same, with improved efficiency and safety vs dextrose-based solutions (Kidney Medicine, Nov 2024) |
| Studies | RED DESERT (PoC, 2021), SAHARA Phase 2a (top-line Nov 2022); both in European Journal of Heart Failure (Apr 2024) | YUKON (Canada) and CHIHUAHUA (Mexico) Phase 1 single-dose; GLP studies in mice and sheep (Feb 2023); MOJAVE US Phase 1/2a — 3 non-randomised patients: mean +326% six-hour urinary sodium excretion and 95% reduction in loop diuretics at 3 months (Mar 2024); randomised cohort of up to 30 patients DSMB-approved but never started for lack of funding |
| Status | Superseded | Clinical stage; not approved anywhere; IP being sold by trustees |
| Target customer | Cardiologists / heart-failure centres; company estimated ~200,000 US HF patients with diuretic-resistant congestion (FY2022 results) | Same |
Other / discontinued
| Offering | Detail |
|---|---|
| alfapump DSR (fully implanted DSR system) | Original concept at IPO (2019) to combine alfapump with DSR; abandoned when DSR was shown to work without the pump — company stated little synergy remained between programmes (FY2024 results) |
| European alfapump sales | Germany was historically the largest market; terminated Q1 2024 |
Financial Narrative
Source basis: FY2021–FY2022 from FY2022 results release (9 Feb 2023); FY2023–FY2024 from FY2024 results release (18 Mar 2025); FY2020 revenue and net loss from Euronext company data (Cofisem); FY2020 year-end cash and equity derived from opening balances in FY2022 release. FY2025 financial statements were never published; H1 2025 data presented separately. EBITDA computed as EBIT plus depreciation (cash-flow statement). Pre-tax income computed as net loss plus income tax expense.
Income statement: notes and sources
Note: diluted EPS not separately reported; with net losses, potential shares are anti-dilutive, so diluted equals basic.
Margins and growth
Revenue CAGR FY2020–FY2024: -42.4% (EUR 963k to EUR 106k). FY2021–FY2024 CAGR: -34.1%.
H1 2025 versus H1 2024 (last published financials)
Source: H1 2025 results release (25 Sep 2025).
Balance sheet
At 30 June 2025: total assets EUR 14,571k; cash EUR 7,314k; short-term financial debts EUR 40,426k; other current financial liabilities EUR 6,586k; total equity EUR -39,175k; losses brought forward EUR -268,954k; first capitalised development costs EUR 264k (IAS 38). Net debt decreased by EUR 2.2m versus end-2024 (H1 2025 report).
Note on working capital: the company described FY2024 and H1 2025 working capital as having "dropped" by EUR 1.44m and EUR 1.83m; arithmetically, the defined measure became less negative (from EUR -4,900k to EUR -3,461k in FY2024), reflecting reduced payables and accruals as spending was cut. The discrepancy is one of sign convention.
Ratios
ROE, ROIC, debt/equity, net debt/EBITDA and interest coverage are not meaningful (negative equity from FY2021 and negative EBIT/EBITDA in every year). Cash conversion cycle is not meaningful given negligible revenue.
Commentary on trends, inflections and drivers
Revenue. Revenue was never a meaningful driver. The FY2022 rebound (EUR 923k) reflected post-COVID resumption of European implants; FY2023 declined as the company deliberately scaled back European selling to concentrate resources on US approval; and the Q1 2024 decision to terminate European commercial activities reduced revenue to EUR 106k in FY2024 and zero in H1 2025. US commercial revenue began only in Q4 2025 and was never reported because FY2025 accounts were not published. Gross margins in the 75–79% range are consistent with an implantable device priced around EUR 20–25k per unit in Europe, but on tiny volumes they are analytically irrelevant.
Operating expenses. The cost base rose from EUR 24.1m (FY2021) to a peak of EUR 30.0m (FY2023) as the company ran the POSEIDON pivotal study, prepared the PMA, and advanced DSR through SAHARA, GLP toxicology and MOJAVE start-up. The FY2024 inflection — a 37% cut to EUR 18.8m — was driven by the end of POSEIDON costs, postponement of the MOJAVE randomised cohort, the European commercial exit, headcount reductions and one-off FY2023 PMA-preparation spend not recurring. H1 2025 opex fell a further 9% even as US launch spending (S&M +91%, supply chain +18%) began, implying an annualised run-rate around EUR 18m — still far above any plausible near-term revenue.
Below-the-line volatility. The net loss widened to EUR 44.7m in FY2024 despite a smaller EBIT loss because of EUR 26.2m of net finance expense, overwhelmingly non-cash fair-value remeasurements of the Kreos loan (as amended in 2024), the September–December 2024 convertible loans and subscription rights (warrants). The same dynamic recurred in H1 2025 (net finance cost EUR 9.6m). These charges are symptomatic of a capital structure layered with convertible and warrant-bearing instruments whose fair values rose as the equity value of the conversion features changed.
Balance sheet. Equity turned negative in FY2021 and deteriorated to EUR -44.4m by FY2024. Total financial debt more than doubled in FY2024 to EUR 40.1m, all classified as current, reflecting fair-value accounting and loan maturity profiles. The company disclosed that, excluding the EUR 4.5m converted on 24 January 2025 and assuming conversion of remaining 2024 convertibles, the underlying principal, interest and fees at end-2024 would have been EUR 13.03m — a material gap between accounting and contractual debt that should inform any recovery analysis. Statutory (Belgian GAAP) net equity was also negative, triggering the Article 7:228 alarm-bell procedure at the May 2026 AGM.
Cash and going concern. Every set of accounts from FY2022 onward carried a material-uncertainty going-concern statement. Year-end cash covered between roughly one and eight months of operating outflows. Financing was obtained in increasingly small and increasingly structured tranches (mandatory convertibles, subordinated convertibles, an equity line with GEM), with runway guidance repeatedly extended by a quarter or two at a time: into Q1 2025 (late 2024), to end-2025 (March 2025), and to at least Q1 2026 (September 2025). The final runway expired in Q2 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Function | Status (Oct 2026) |
|---|---|---|---|
Sequana Medical NV | Belgium | Parent, registered office, listed entity | Bankrupt (30 Jun 2026) |
Sequana Medical NV — Zurich branch | Switzerland | alfapump assembly, engineering, QA/RA, supply chain (35 employees) | Part of bankrupt estate (branch of NV) |
DSRCo BV | Belgium | Vehicle for DSR programme / IP | Bankrupt (30 Jun 2026) |
Sequana Medical US Inc | United States | US commercial operations (4 employees) | Status not publicly disclosed |
Sequana Medical GmbH | Germany (implied) | Historic European commercial subsidiary (referenced in FY2024 statutory board report) | Status not publicly disclosed |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Total revenue — alfapump (EUR K) | 371 | 923 | 712 | 106 |
DSR programme revenue (EUR K) | 0 | 0 | 0 | 0 |
EBIT — total company (EUR K) | -22,614 | -28,094 | -28,862 | -18,223 |
Revenue YoY growth (%) | -61.5 | 148.8 | -22.9 | -85.1 |
Share of total revenue — alfapump (%) | 100 | 100 | 100 | 100 |
Income Statement and Per-Share Data
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Revenue (EUR K) | 963 | 371 | 923 | 712 | 106 |
Cost of goods sold (EUR K) | — | -77 | -205 | -164 | -26 |
Gross profit (EUR K) | — | 294 | 718 | 548 | 79 |
Sales & Marketing (EUR K) | — | -2,079 | -2,240 | -1,799 | -1,058 |
Clinical (EUR K) | — | -7,798 | -9,773 | -6,947 | -3,174 |
Quality & Regulatory (EUR K) | — | -3,215 | -3,632 | -5,586 | -3,243 |
Supply Chain (EUR K) | — | -2,716 | -3,158 | -4,724 | -3,315 |
Engineering (EUR K) | — | -3,206 | -3,853 | -4,041 | -1,683 |
General & Administration (EUR K) | — | -5,098 | -6,687 | -6,943 | -6,313 |
Total operating expenses (EUR K) | — | -24,112 | -29,343 | -30,040 | -18,786 |
Other income (EUR K) | — | 1,205 | 530 | 629 | 484 |
Operating income / EBIT (EUR K) | — | -22,614 | -28,094 | -28,862 | -18,223 |
Depreciation (EUR K) | — | 409 | 312 | 661 | 615 |
EBITDA (EUR K, computed) | — | -22,205 | -27,782 | -28,201 | -17,608 |
Net finance result (EUR K) | — | -608 | -2,282 | -3,236 | -26,150 |
Pre-tax income (EUR K, computed) | — | -23,222 | -30,376 | -32,098 | -44,374 |
Income tax expense (EUR K) | — | -393 | -387 | -466 | -280 |
Net income (EUR K) | -19,106 | -23,615 | -30,763 | -32,564 | -44,654 |
EPS basic (EUR) | — | -1.30 | -1.35 | -1.22 | -1.22 |
EPS diluted (EUR) | — | -1.30 | -1.35 | -1.22 | -1.22 |
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Gross margin (%) | 79.2 | 77.8 | 77.0 | 74.5 |
EBIT margin (%) | -6,095 | -3,044 | -4,054 | -17,192 |
EBITDA margin (%) | -5,985 | -3,010 | -3,961 | -16,611 |
Net margin (%) | -6,365 | -3,333 | -4,574 | -42,126 |
Revenue YoY growth (%) | -61.5 | 148.8 | -22.9 | -85.1 |
Income Statement and Key Financials (EUR)
| Metric | H1 2024 | H1 2025 |
|---|---|---|
Revenue (EUR K) | 106 | 0 |
Total operating expenses (EUR K) | -9,816 | -8,966 |
EBIT (EUR K) | -9,595 | -8,582 |
Finance income (EUR K) | 3,172 | 3,193 |
Finance cost (EUR K) | -4,512 | -12,763 |
Net loss (EUR K) | -11,080 | -18,278 |
Basic LPS (EUR) | -0.34 | -0.35 |
Cash at period end (EUR K) | 4,153 | 7,314 |
Operating cash flow (EUR K) | -12,355 | -9,723 |
Financing cash flow (EUR K) | 13,962 | 13,258 |
Balance Sheet
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Total assets (EUR K) | — | 14,705 | 26,025 | 10,101 | 9,944 |
Cash and cash equivalents (EUR K) | 11,016 | 9,600 | 18,875 | 2,584 | 3,807 |
Inventory (EUR K) | — | 2,139 | 2,621 | 2,296 | 2,046 |
Short-term financial debt (EUR K) | — | 0 | 4,483 | 7,818 | 39,698 |
Long-term financial debt (EUR K) | — | 7,325 | 12,193 | 8,969 | 0 |
Lease debt total (EUR K) | — | 760 | 916 | 733 | 413 |
Other current financial liabilities (EUR K) | — | 0 | 1,569 | 2,767 | 7,387 |
Total financial and lease debt (EUR K) | — | 8,085 | 17,601 | 17,520 | 40,111 |
Net debt (EUR K, company definition) | — | -1,515 | -1,274 | 14,936 | 36,304 |
Total equity (EUR K) | 113 | -787 | -2,153 | -19,465 | -44,379 |
Goodwill and intangibles (EUR K) | 0 | 0 | 0 | 0 | 0 |
Working capital (EUR K, company definition) | — | -3,607 | -4,576 | -4,900 | -3,461 |
Accumulated losses brought forward (EUR K) | -119,080 | -142,695 | -173,458 | -206,022 | -250,676 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Operating cash flow (EUR K) | -23,617 | -27,482 | -29,063 | -20,258 |
Capex — tangible (EUR K) | -326 | -677 | -711 | -95 |
Free cash flow (EUR K, computed) | -23,943 | -28,159 | -29,774 | -20,353 |
Equity proceeds (EUR K) | 22,771 | 28,420 | 15,786 | 11,665 |
Debt proceeds (EUR K) | 0 | 9,626 | 0 | 10,682 |
Interest paid (EUR K) | 0 | -315 | -929 | -162 |
Dividends paid (EUR K) | 0 | 0 | 0 | 0 |
Share buybacks (EUR K) | 0 | 0 | 0 | 0 |
Net change in cash (EUR K) | -1,520 | 9,189 | -16,324 | 1,197 |
Financial Ratios (x) and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Current ratio (x) | 1.80 | 1.52 | 0.32 | 0.12 |
ROA (%, year-end assets) | -161 | -118 | -322 | -449 |
Asset turnover (x, year-end assets) | 0.025 | 0.035 | 0.070 | 0.011 |
Cash runway at year-end (months, cash / avg monthly operating outflow) | 4.9 | 8.2 | 1.1 | 2.3 |
Revenue by Region
| Region (EUR K) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Europe (all countries) | 923 | 712 | 106 |
United States | 0 | 0 | 0 |
Rest of world | 0 | 0 | 0 |
Total | 923 | 712 | 106 |
Region growth (%)
| Region growth (%) | FY2023 | FY2024 |
|---|---|---|
Europe | -22.9 | -85.1 |
Balance Sheet (FY2019–FY2025)
| Metric | FY2019 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
Gross equity / CLA financing raised (EUR Mn) | 27.5 | 22.5 | 28.4 | 15.8 | 22.1 | 13.6 |
Share Price History
| Date | Price (EUR) | Event |
|---|---|---|
11 Feb 2019 | 8.50 | IPO price |
Mar 2022 | 5.50 | Equity placement price |
27 Apr 2026 | 0.4581 | GEM subscription price (last pre-suspension issuance reference) |
28 Apr 2026 onward | Suspended | — |
Valuation Snapshot
| Multiple | Value |
|---|---|
P/E | Not meaningful (losses; bankrupt) |
EV/Sales | Not meaningful (EUR 0.1m FY2024 revenue; FY2025 unpublished) |
P/B | Not meaningful (negative book value) |
Capital Markets
| Item | Detail |
|---|---|
Analyst coverage | Company listed analyst coverage page; Edison Investment Research (paid research client) published rNPV-based valuations (e.g., EUR 12.38/share in 2022; pipeline rNPV EUR 344m in Feb 2023); consensus not available post-suspension |
Dividend history / policy | No dividends ever paid; none possible |
Credit ratings | None (unrated) |
Debt maturity profile | All financial debt classified current at FY2024 (EUR 39.7m short-term financial debt); contractual principal plus accrued interest and fees ~EUR 13.03m on a pro-forma basis after Jan 2025 conversions (FY2024 results). Detailed maturity ladder post-March 2025 restructuring not publicly disclosed. Now subject to bankruptcy claims process. |
Analyst Conclusions
Management guidance. None outstanding. The last operational guidance (≥70 US implants at eight centres by end-Q1 2026, then ~5 new centres per quarter) was effectively withdrawn by the 28 April 2026 strategic review and superseded by the bankruptcy. Consensus growth expectations: none (coverage lapsed).
Bull case (for creditors / acquirers of the assets, not equity holders)
-
An acquirer can buy an FDA-approved, NTAP-supported Class III device with pivotal data showing 100% median reduction in paracentesis, free of the EUR 40m accounting debt stack and the convertible/warrant overhang.
-
The alfapump has >1,000 implants of clinical history, MDR certification and early US adopters (five centres, ~20 in pipeline as of Feb 2026), shortening a buyer's time to scale.
-
DSR IP, backed by peer-reviewed RED DESERT/SAHARA data and a DSMB-approved randomised protocol, could attract a heart-failure strategic at modest cost.
Bear case
-
Equity holders are very likely to receive nothing: statutory and IFRS equity are negative, creditors rank ahead and shares remain suspended.
-
Asset value decays quickly in bankruptcy — the 35-person Zurich assembly team, hospital contracts and regulatory maintenance require funding the estate may not provide.
-
Commercial traction was weak even before insolvency (single-digit implants against a 70-implant target), suggesting market adoption may be structurally slower than the company's USD 2bn opportunity framing implied.
Key catalysts and monitorables (next 12 months)
Concluding analyst verdict. Sequana Medical is a textbook case of regulatory success outrunning financial capacity. Over two decades the company did most of what a medtech innovator is supposed to do: it invented a genuinely novel device, built a European implant base, ran a well-executed North American pivotal study that exceeded its effectiveness endpoints, won FDA approval earlier than the market expected, secured CPT III codes and, critically, an NTAP worth up to USD 21,450 per inpatient case. It also generated a credible second platform in DSR with peer-reviewed evidence in diuretic-resistant heart failure. Yet none of this translated into revenue before the money ran out. The decision to exit Europe in 2024 removed the only income stream; the US launch began roughly a year after approval and then progressed through slow hospital value-analysis and contracting cycles; and the capital structure — negative equity since 2021, venture debt, mandatory and subordinated convertibles, warrants and a GEM equity line — made each successive raise smaller, more dilutive and more expensive. By April 2026 the company could not publish FY2025 accounts, and by June it could not meet obligations as they fell due. For equity investors, the analytical question is closed: the shares are suspended, book equity is deeply negative, and creditors rank ahead, so the expected recovery for shareholders is effectively zero. The more interesting question is for strategic acquirers and creditors. The alfapump's PMA, reimbursement codes, clinical dossier and installed base represent assets that cost well over EUR 200m to create and may now be acquired at a fraction of that, provided the Zurich know-how and US site relationships survive the bankruptcy timetable. DSR is an option for a cardiorenal specialist. The verdict: an investment failure, but a potentially valuable technology salvage — monitor the trustees' sale process, not the stock.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education |
|---|---|---|---|---|
Ian Crosbie | CEO; executive director | CEO since 2016; director since 2019 | CFO, GC Aesthetics (Dublin); SVP Corporate Development, Circassia (led GBP 210m IPO); MD Healthcare Investment Banking, Jefferies; Director, Deutsche Bank | Engineering, Economics and Management, Oxford |
Kirsten Van Bockstaele | CFO | — | VP Finance, Fagron North America; CFO, Arseus Dental & Medical Solutions; Omega Pharma; PwC | Business Economics (EHSAL); Financial and Fiscal Sciences (Antwerp) |
Gijs Klarenbeek, MD | Chief Medical Officer | — | Director Medical Affairs Europe, Boston Scientific; Worldwide Medical Director Clinical Research, J&J (Cordis); Sanofi, AstraZeneca | MD (Leuven); business administration (IFB) |
Martijn Blom | Chief Commercial Officer | — | Director International Marketing, Myriad Genetics; Pulmonx; Alere | Economics/marketing (Breda) |
Mark Singer | Head of US Commercial (Florida) | Engaged since 2024; role from 2025 | VP National Accounts, NuVasive; CCO, Carlsmed; CCO, Galen Robotics | — |
Timur Resch | Global VP QM/QA/RA; PRRC | — | Medela; Schaerer Medical; Synspace | Medical technology engineering (Lübeck) |
Andreas Wirth | VP Engineering | — | Director R&D, Carl Zeiss Meditec; Schott; medi Group; Lonza | PhD applied science; physics (Osnabrück) |
Dragomir Lakic | Global VP Manufacturing | — | Smith+Nephew; Zimmer Biomet (12 years) | Engineering and Management; MBA (ZHAW) |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Independence | Background |
|---|---|---|---|
Pierre Chauvineau | Chair | Independent | 20 years Medtronic; Cameron Health (acquired by Boston Scientific 2012); led Boston Scientific's largest European BU; chair of Aurigen Medical, Aryballe |
Ian Crosbie | Executive director, CEO | Executive | See above |
Rudy Dekeyser | Non-executive | Non-independent (EQT representative) | Partner, EQT; head of EQT Health Economics funds; VIB co-founder |
Wim Ottevaere (WIOT BV) | Non-executive | Independent | Former CFO Biotalys, Ablynx, Innogenetics |
Jackie Fielding | Non-executive | Independent | 28 years Medtronic (VP UK/Ireland); NED at NICE |
Alexandra Clyde | Non-executive | Independent | 26 years Medtronic; Corporate SVP Global Health Economics, Policy and Reimbursement |
Ids van der Weij | Non-executive | Non-independent (Partners in Equity V) | Managing Partner, Partners in Equity V |
Major Shareholders
| Holder | Nature | Stake |
|---|---|---|
Partners in Equity V B.V. | Lead investor since March 2022; 2024 and 2025 CLA lender | — |
EQT Health Economics 3 Coöperatief U.A. | Shareholder (EQT lists entry 2024); 2025 CLA lender | — |
SFPIM (Belgian Federal Holding and Investment Company) | Shareholder since IPO; 2025 CLA investor | — |
Rosetta Capital | Acquired NeoMed V stake (2022/23); 2024 CLA | — |
BlackRock Kreos (Kreos Capital) | Lender; equity via loan conversions and warrants; transparency notifications 8 Dec 2025 and 31 Dec 2025 | — |
GEM Global Yield LLC SCS | Equity line counterparty; transient holdings via subscriptions and share lending | — |
Sensinnovat | 2020 loan, partially converted Jan 2025 | — |
Historic VCs (LSP, VI Partners, BioMedPartners, Capricorn) | Pre-IPO investors | Current stakes not publicly disclosed |
Insiders | Management and directors | — |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor / alternative | Owner | Modality | Positioning versus alfapump |
|---|---|---|---|
Large-volume (therapeutic) paracentesis | Standard of care; kits from multiple suppliers (e.g., BD, Cardinal Health) | Repeated needle drainage | Cheap, universal, but burdensome and repeated weekly/monthly; alfapump's core displacement target |
TIPS (Viatorr stent-graft) | W. L. Gore & Associates (private) | Transjugular intrahepatic portosystemic shunt | Guideline-endorsed for refractory ascites; contraindicated or poorly tolerated in some patients (encephalopathy, liver function) |
Tunnelled peritoneal catheters (PleurX) | BD | Indwelling drainage catheter | Used mainly in malignant ascites; infection risk |
Aspira peritoneal drainage system | Merit Medical | Indwelling drainage catheter | Malignant/refractory ascites drainage |
Rocket IPC | Rocket Medical | Indwelling drainage catheter | Malignant ascites |
Long-term albumin infusion | Grifols, CSL Behring, Takeda, Octapharma | Plasma-derived therapy | Adjunct to paracentesis; evidence for outcomes in decompensated cirrhosis |
Peritoneovenous (Denver) shunt | BD (CareFusion heritage) | Surgical shunt | Largely abandoned due to complications |
Liver transplantation | Transplant centres | Definitive cure | Limited by organ supply; alfapump positioned as bridge |
Emerging MASH/cirrhosis therapies | Madrigal (Rezdiffra), Novo Nordisk (semaglutide in MASH) | Disease-modifying drugs | Long-term could reduce progression to decompensation |
Loop diuretics (furosemide, torsemide, bumetanide) and sequential nephron blockade | Generic | Pharmacological | Standard of care; diuretic resistance is DSR's target |
Ultrafiltration (Aquadeus) | Nuwellis | Extracorporeal | Hospital-based fluid removal; mixed outcomes evidence |
Reprieve System | Reprieve Cardiovascular | Automated decongestion with urine-matched fluid replacement | Clinical-stage competitor in acute decongestion |
Aortix | Procyrion | Intra-aortic pump for cardiorenal syndrome | Clinical-stage |
Peritoneal dialysis solutions (Extraneal icodextrin) | Baxter; Fresenius | Peritoneal therapy | Adjacent technology; DSR 2.0 uses icodextrin |
SGLT2 inhibitors / finerenone | AstraZeneca, Boehringer Ingelheim/Lilly, Bayer | Pharmacological | Reduce HF hospitalisations broadly, shrinking diuretic-resistant pool |
Peer Comparison FY2024
| Metric | Sequana Medical (FY2024) | BD (PleurX) | Merit Medical (Aspira) |
|---|---|---|---|
Revenue | EUR 0.1m | Diversified multi-billion group; product-line revenue not disclosed | Diversified group; product-line revenue not disclosed |
Revenue growth | -85.1% | Not comparable | Not comparable |
Gross margin | 74.5% | Not comparable | Not comparable |
Operating margin | -17,192% | Not comparable | Not comparable |
R&D intensity (proxy) | 7,642% of revenue | Not comparable | Not comparable |



